Connect with us

Technology

Philips and Singapore General Hospital to advance medical imaging capabilities in Asia Pacific with first-of-its-kind MRI training collaboration

Published

on

Singapore General Hospital (SGH) enhances its radiographers’ capabilities in MR clinical practice through Philips Clinical Application Training and an Magnetic Resonance Imaging (MRI) Training Centre that serves as a reference site.This collaboration extends SGH’s MR expertise to other public and private hospitals in Singapore and beyond, to upskill healthcare staff and improve patient care in Asia Pacific.

SINGAPORE, Dec. 9, 2024 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announces its strategic collaboration with Singapore General Hospital (SGH) to set up a first-of-its-kind Magnetic Resonance Imaging (MRI) Training Centre in Singapore. Commencing on December 9, 2024, the collaboration enhances SGH’s efforts to advance medical imaging education and capabilities through the opening of the training centre to public and private hospitals in Singapore and Asia Pacific (APAC).

With 71% of healthcare leaders in APAC concerned about staff shortages resulting in delays in care for patients [1], digital health technologies become increasingly vital in helping people get the care they need when they need it, by streamlining workflows and seamlessly connecting data end-to-end to bring the most clinically valuable and patient-centric insights to care teams. And training and education are key components in supporting digital upskilling and continuous learning as technology advances.

“We have a long-standing relationship with Singapore General Hospital. We are excited to expand our partnership and play a part in elevating the diagnostic standards and capabilities in Singapore and Asia Pacific,” says Dr. Mark Burby, Vice President of Health Systems, Philips APAC. “This collaboration aligns with Philips’ vision of delivering better care for more people by raising the standards of care delivery. It is also part of our steady commitment to strategically work together with key health system stakeholders to improve the adoption and deepen the understanding of the latest imaging innovations in radiology.”

Deepening clinical education and enhancing staff expertise in Singapore and beyond

As part of the collaboration, two SGH MRI radiographers will undergo Philips Clinical Application Training using a Train-the-Trainer approach. This is Philips’ signature training program typically for its application specialists. The extensive training program will equip and empower SGH radiographers to then share the latest and in-depth expertise in MR clinical practice with others.

“Our commitment to equipping colleagues with the latest technological advancements and knowledge is reinforced through our collaboration with Philips. It enables us to enhance our capabilities in managing increasingly complex patient conditions, which is crucial in today’s healthcare landscape. Moreover, the partnership has the potential to yield positive outcomes not only for Singapore General Hospital but also for healthcare providers across the Asia-Pacific region,” says Associate Professor Andrew Tan, Chairman, Division of Radiological Sciences, SGH. “This is a great testament to what can be accomplished when organizations with a shared vision and purpose come together.”

Dawn of a new APAC hub for clinical application excellence in MR practice

An MRI Training Centre will also be set up in SGH as an educational hub for other radiographers from across the APAC region. The room is equipped for SGH to facilitate the upskilling of radiographers with the latest MRI clinical applications and host educational workshops, seminars and trainings across the public or private sectors.

SGH will serve as a key reference site for Singapore and overseas healthcare institutions on best practices, workflows, techniques, real-world operations and clinical experiences around the Philips MR ecosystem and technology. This is a significant benefit, given that nearly two in five (37%) healthcare leaders in Singapore identified other healthcare organizations as a key collaborator in helping to improve healthcare for the patients and communities they serve, according to Philips Future Health Index 2024 Singapore report.

“We welcome and value such collaborations between healthcare providers and technology innovators such as ourselves,” says Dr. Mark Burby, Vice President of Health Systems, Philips APAC. “They are critical to ensure the region’s health systems are maximizing the impact of available innovations to alleviate pain points, expanding patient and staff access to such technology and creating platforms for knowledge and best practice sharing within and across national borders.”

[1] Philips Future Health Index 2024 Report: APAC Healthcare leaders taking bold and thoughtful changes to deliver better care for more people. Philips. From: https://www.philips.com.sg/a-w/about/news/archive/standard/news/articles/2024/20240916-philips-future-health-index-2024-report-apac-healthcare-leaders-taking-bold-and-thoughtful-changes-to-deliver-better-care-for-more-people.html

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Singapore General Hospital

Singapore General Hospital, established in 1821, is the largest tertiary hospital in Singapore and ranked among the world’s best. It provides the most comprehensive patient-centred care with over 50 clinical specialties on its campus. As an Academic Medical Centre, it takes pride in training healthcare professionals and conducting cutting edge research to meet evolving needs of the nation as well as the region. Driven by a strong sense of purpose, SGH is committed to give of its best to heal and bring hope, as it has for over 200 years. For more information, please visit www.sgh.com.sg

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/philips-and-singapore-general-hospital-to-advance-medical-imaging-capabilities-in-asia-pacific-with-first-of-its-kind-mri-training-collaboration-302325951.html

SOURCE Royal Philips

Continue Reading

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

on

By

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Continue Reading

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

on

By

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.

Continue Reading

Technology

Bulletin from Sivers Semiconductors AB’s Extraordinary General Meeting on 22 October 2026

Published

on

By

KISTA, Sweden, Oct. 22, 2026 /PRNewswire/ — The Extraordinary General Meeting in Sivers Semiconductors AB (the “Company”) was held on 22 October 2026 and in particular the following resolutions were resolved.

Election of auditor

The Extraordinary General Meeting resolved, in accordance with the Nomination Committee’s proposal, to terminate the assignment of the Company’s auditor Deloitte AB and to elect Ernst & Young AB as new auditor for the period until the close of the next Annual General Meeting.

Resolution on a long-term incentive program

The Extraordinary General Meeting resolved to introduce a long-term incentive program (the “P11”) for employees of the group in the United States, Scotland, Sweden, India and China.

P11 comprises a maximum of 7,280,000 stock options entitling to purchase of the same number of shares, corresponding to approximately 2.0 per cent of the shares and votes in the Company after dilution. The stock options are granted free of charge, are not subject to any performance conditions, and may not be transferred or pledged. Each vested stock option entitles the employee to acquire one ordinary share between the third and the sixth anniversary of the date of grant, at a price corresponding to 110 per cent of the volume-weighted average price of the Company’s share on Nasdaq Stockholm during the five trading days immediately preceding the date of grant.

Resolution to authorise the Board of Directors to resolve on directed issue of Series C shares

The Extraordinary General Meeting resolved to authorise the Board of Directors to, until the next Annual General Meeting, resolve on a new issue of no more than 7,280,000 Series C shares to be subscribed for by a bank or securities company at a subscription price corresponding to the quota value.

The purpose is to secure delivery of shares to participants under the Company’s outstanding incentive programs and payment of related social security charges. The Series C shares will be reclassified into ordinary shares before transfer to participants.

Resolution to authorise the Board of Directors to resolve on repurchase of Series C shares and transfer of ordinary shares to secure payment of social security charges

The Extraordinary General Meeting resolved to authorise the Board of Directors to, until the next Annual General Meeting, resolve on repurchases of all outstanding Series C shares, at a price corresponding to the quota value.

The Board of Directors was further authorised to, until the next Annual General Meeting, transfer own ordinary shares on Nasdaq Stockholm within the applicable price range, or outside Nasdaq Stockholm to a bank or securities company with deviation from the shareholders’ preferential rights at such market discount as the Board of Directors deems appropriate, to the extent required to secure payment of social security charges related to the Company’s outstanding incentive programs.

For more information, please contact:

Vickram Vathulya, CEO, Sivers Semiconductors AB (publ)

Email: ir@sivers-semiconductors.com

Tel: +46 (0)8 703 68 00

About Sivers Semiconductors

Sivers Semiconductors is a critical enabler of a greener data economy with energy efficient photonics & wireless solutions. Our differentiated high precision laser and RF beamformer technologies help our customers in key markets such as AI Datacenters, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. For additional information, please visit us at: www.sivers-semiconductors.com. (SIVE.ST)

CONTACT:

Media Contact   
Tyler Weiland 
Shelton Group
+1-972-571-7834
tweiland@sheltongroup.com

Company Contact
Heine Thorsgaard
CFO 
ir@sivers-semiconductors.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sivers-semiconductors/r/bulletin-from-sivers-semiconductors-ab-s-extraordinary-general-meeting-on-22-october-2026,c4414255

View original content:https://www.prnewswire.com/news-releases/bulletin-from-sivers-semiconductors-abs-extraordinary-general-meeting-on-22-october-2026-302917519.html

SOURCE Sivers Semiconductors

Continue Reading

Trending